Early-onset parkinsonism-intellectual disability syndrome

Early-onset parkinsonism-intellectual disability syndrome, also known as Waisman syndrome, is a rare X-linked neurological disorder characterized by the combination of early-onset parkinsonism and intellectual disability. The condition primarily affects the central nervous system, with affected individuals typically presenting with mild to moderate intellectual disability in childhood, followed by the development of parkinsonian features in adolescence or early adulthood. Parkinsonian signs include bradykinesia (slowness of movement), rigidity, tremor, and postural instability. The syndrome is caused by mutations in the RAB39B gene located on the X chromosome, which plays a role in neuronal development and synaptic function. Because the condition is X-linked recessive, it predominantly affects males, while carrier females are generally unaffected or may show milder symptoms. Some patients may also exhibit behavioral difficulties, seizures, and macrocephaly. Brain imaging may reveal nonspecific findings, though some cases have shown evidence of iron accumulation or dopaminergic neuron loss in the substantia nigra, consistent with the parkinsonian features. There is currently no cure for early-onset parkinsonism-intellectual disability syndrome. Treatment is symptomatic and supportive. Parkinsonian symptoms may respond partially to levodopa or dopamine agonist therapy, though the response can be variable and may diminish over time. Management of intellectual disability involves educational support, speech therapy, occupational therapy, and behavioral interventions. Seizures, when present, are managed with standard antiepileptic medications. A multidisciplinary approach involving neurologists, geneticists, and developmental specialists is recommended for optimal care.

Common questions about Early-onset parkinsonism-intellectual disability syndrome